Previous Close | 5.60 |
Open | 5.62 |
Bid | 5.51 x 900 |
Ask | 6.21 x 1000 |
Day's Range | 5.58 - 5.90 |
52 Week Range | 4.29 - 14.45 |
Volume | |
Avg. Volume | 315,522 |
Market Cap | 5.17M |
Beta (5Y Monthly) | 1.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -11.83 |
Earnings Date | Mar 28, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.13 |
Subscribe to Yahoo Finance Plus to view Fair Value for HSDT
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System (“HCPCS”) Level II codes for the Portable
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in chronic stroke survivors ---- Results will support efforts to achieve U.S. authorization under PoNS’s breakthrough designation for stroke -- NEWTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on del